The Technical Analyst
Select Language :
Hoth Therapeutics Inc [HOTH]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Hoth Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Hoth Therapeutics Inc is listed at the  Exchange

10.14% $1.520

America/New_York / 28 mar 2024 @ 16:00


Hoth Therapeutics Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 6.61 mill
EPS: -4.71
P/E: -0.320
Earnings Date: Mar 31, 2024
SharesOutstanding: 4.35 mill
Avg Daily Volume: 0.494 mill
RATING 2024-03-28
B
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Sell
Return On Asset: Sell
DE: Sell
P/E: Sell
Price To Book: Neutral
QUARTER GROWTHS
2/223/224/221/232/233/23
Revenuen/an/an/an/an/an/a
Gr.Profit
Ebit
Asset
Debtn/an/an/an/an/an/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.320 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.05x
Company: PE -0.320 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$2.71
(78.26%) $1.189
Date: 2024-03-29
Expected Trading Range (DAY)

$ 1.440 - 1.600

( +/- 5.26%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-01-05 Springer Graig Buy 100 000 Options
2024-01-05 Springer Graig Buy 25 000 Options
2024-01-05 Sarnoff David Buy 25 000 Options
2024-01-05 Pavell Jeff Buy 25 000 Options
2024-01-05 Linsley Wayne Buy 25 000 Options
INSIDER POWER
100.00
Last 63 transactions
Buy: 4 493 741 | Sell: 2 121 250

Forecast: 16:00 - $1.514

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $1.514
Forecast 2: 16:00 - $1.514
Forecast 3: 16:00 - $1.514
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $1.520 (10.14% )
Volume 0.253 mill
Avg. Vol. 0.494 mill
% of Avg. Vol 51.09 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Hoth Therapeutics Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Hoth Therapeutics Inc

RSI

Intraday RSI14 chart for Hoth Therapeutics Inc

Last 10 Buy & Sell Signals For HOTH

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Hoth Therapeutics Inc

HOTH

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Last 10 Buy Signals

Date Signal @
HBTCUSDMar 29 - 04:3834 558
DESOUSDMar 29 - 04:3931.41
ARUSDMar 29 - 04:28$41.19
KCSUSDMar 29 - 04:24$11.87
FTNUSDMar 29 - 04:141.819
ORAIUSDMar 29 - 04:0814.59
IONUSDMar 29 - 04:08452.00
MXUSDMar 29 - 04:07$4.21
RETHUSDMar 29 - 04:043 905.62
ABTUSDMar 29 - 04:041.978

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.